Parkinson’s Disease: How Stem Cell Research Will Make a Difference
The New York Stem Cell Foundation (NYSCF) held its sixth annual spring public outreach event to bring together leading stem cell scientists with patient advocates to describe current efforts to apply stem cell research to finding new treatments and cures for Parkinson’s disease.
The New York Stem Cell Foundation (NYSCF) held its sixth annual spring public outreach event to bring together leading stem cell scientists with patient advocates to describe current efforts to apply stem cell research to finding new treatments and cures for Parkinson’s disease.
Thursday, April 7, 2011 at 6:30pm
The TimesCenter, 242 West 41st Street
This year’s panel was moderated by journalist Michael Kinsley, columnist at Politico and co-founder of Slate Magazine, and featured:
- Dr. Kevin Eggan, Chief Scientific Officer at The New York Stem Cell Foundation, and Associate Professor of Stem Cell and Regenerative Medicine at The Harvard Stem Cell Institute
- Robin Elliott, Executive Director of the Parkinson’s Disease Foundation
- Melissa J. Nirenberg, Assistant Professor of Neurology at Weill Cornell Medical College and Associate Director at Weill Cornell Parkinson’s Disease & Movement Disorders Institute
- Susan L. Solomon, Chief Executive Officer at The New York Stem Cell Foundation
- Dr. Lorenz Studer, Director of the Sloan-Kettering Center for Stem Cell Biology and Professor of Developmental Biology and Department of Neurosurgery at Memorial Sloan-Kettering Cancer Center
In past years, NYSCF’s public outreach panels have focused on stem cell research in relation to Alzheimer’s disease, diabetes, the important role stem cell research plays in accelerating research, and the political controversy surrounding this groundbreaking science. Previous notable panel participants include: Nobel Laureate and Director of the National Cancer Institute, Dr. Harold Varmus; ten-time Olympic medalist, Gary Hall, Jr.; artist, Chuck Close; patient advocates Michael J. Fox and Alexandra Reeve; and Greg Simon, Senior Vice President of Worldwide Policy at Pfizer. The 2010 panel had our best response to date and was at capacity with over 400 attendees.
As part of NYSCF’s ongoing public outreach and education initiative, this event was free and open to the public. However, if you would like to assist us in underwriting the cost of similar future program and support our ongoing work, we would be very grateful.
Click here to donate »